WntResearch develops a new type of cancer drug based on groundbreaking research that shows that the body-wise protein Wnt-5a plays an important role in the ability of the tumor cells to move and spread in the body. The vast majority of people who die in cancer do so as a result of tumor proliferation (metastasis) and the need for specific treatment to counteract this is therefore very large. WntResearch’s most advanced drug candidate, Foxy-5, has been shown to reduce the mobility of tumor cells, thereby preventing the appearance of metastases, in preclinical experimental models. The results from a recently completed Phase 1b study demonstrate a favorable safety profile and pharmacokinetics as well as indications of biological activity.
Why should one consider adding your company into their portfolio?
WntResearch develops a novel class of medicines aiming at preventing cancer spread. Today, there are no products on the market to prevent metastasis, which means that WntResearch has the opportunity to become the first company with a drug in a whole new class. Global sales of cancer drugs were estimated to be more than USD 120 billion in 2018. This makes the disease area the largest in the pharmaceutical market where no product on the market is specifically targeted at tumour spreading.
What have been the milestones so far in your company development?
WntResearch develops a unique cancer treatment preventing tumour cells from spreading to form metastasis. After a successful phase 1b-study, the latest milestones for our company was the start of our clinical Ph 2 programme in early 2019 and also a successful financing round to allow us to commence our study.
What are your priorities within 2019/20?
With current financing we are fully focused on our clinical trial for Foxy-5, but also to come to a conclusion with respect to another of our projects, Box-5 in psoriasis.
What are your most important markets, segments and customers?
The need for products that prevent metastasis is very large. As we are a clinical development company with no product on the market yet, the main customer would be a partner from the pharmaceutical industy. A global partner would be the most attractive for us, but we will also consider reginal partners for our main programme, Foxy-5.
Where do you see the company five years from now?
Our main target is to find a partner for our lead compound Foxy-5 and with positive data the most likely scenario would be either out-licensing of the project for certain indications or an acquisition of the company. Our expectation is that this will happen within the next 2-3 years. Five years is normally a long-term perspective for a pharmaceutical company, we foresee critical information from our Ph 2 program already within a year.